OMRON (6645) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
10 Nov, 2026Executive summary
H1 revenue rose 22.9% YoY to ¥425.3bn and operating profit increased 161.5% to ¥40.6bn; profit attributable to owners reached ¥27.4bn.
Q2 revenue grew 20.0% YoY to ¥215.4bn and operating profit rose 123.1% to ¥21.7bn; IAB, HCB and DSB grew, while SSB declined.
Financial highlights
H1 gross profit rose 28.7% to ¥203.0bn; gross margin expanded 2.1 points to 47.7%, and operating margin rose 5.1 points to 9.5%.
Q2 gross profit increased 28.6% to ¥105.5bn and gross margin rose 3.3 points to 49.0%; operating margin reached 10.1%, up 4.7 points.
H1 profit from continuing operations was ¥30.5bn versus ¥8.9bn; profit attributable to shareholders was ¥27.4bn versus ¥4.6bn.
Profit for the period was ¥28.5bn, including a ¥2.0bn discontinued-operations loss; comprehensive income was ¥26.4bn.
Outlook and guidance
Full-year revenue guidance was raised to ¥920.0bn, operating profit to ¥88.0bn and profit attributable to owners to ¥43.0bn.
Forecast profit from continuing operations is ¥60.5bn; basic EPS is ¥307.68 using continuing-operations profit and ¥218.68 inclusive of discontinued operations.
Segment forecasts: IAB revenue ¥540bn and operating profit ¥72bn; HCB ¥165bn and ¥18bn; SSB ¥148bn and ¥19.5bn; DSB ¥62bn and ¥5bn.
Interim dividend is ¥55 per share and full-year dividend guidance remains ¥110; Q3 onward FX assumptions are USD/JPY 155, EUR/JPY 180 and CNY/JPY 23.
Latest events from OMRON
- OnLogic adds industrial PCs and North American reach, with $400 million+ revenue targeted by FY2030.6645
M&A announcement - Profit and revenue soared in Q1, prompting an upward revision to full-year guidance.6645
Q1 2027 - FY2026/27 outlook projects robust growth, higher dividends, and strategic M&A focus in IAB.6645
Q4 2026 - Revenue and net sales up YoY, net income nearly doubled, and full-year guidance raised.6645
Q3 2026 - Sales up, profit down; guidance raised as automation and data outperform, healthcare lags.6645
Q2 2026 - Net income rebounded to ¥6.8bn as automation and device growth offset healthcare weakness.6645
Q1 2026 - Sales and profit fell sharply on restructuring costs, but full-year outlook is maintained.6645
Q1 2025 - Full-year profit guidance raised and dividends maintained despite lower sales and restructuring costs.6645
Q2 2025 - Profits surged on margin gains; FY2025/26 outlook cautious amid tariff risks.6645
Q4 2025